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*Staphylococcus aureus* is a highly virulent, Gram-positive bacterial pathogen, capable of causing a variety of ailments throughout the human body. The emergence of methicillin-resistant *S. aureus* (MRSA) strains that are resistant to last-resort antibiotics demonstrates the urgent need for new treatments and therapies to prevent and treat *S. aureus* infections. Previously, we have performed studies to identify novel antimicrobial compounds that could be used to treat strains of MRSA that are resistant to multiple classes of antibiotics ([@B1]--[@B5]). In these studies, we employed an extensively drug-resistant strain of MRSA (strain CBD-635) isolated from a sepsis patient at Tampa General Hospital. Pulsed-field gel electrophoresis (PFGE) analysis demonstrated that CBD-635 is from the USA100 lineage and that the isolate is resistant to a variety of antimicrobial compounds, including methicillin, centhromycin, azithromycin, erythromycin, clindamycin, ampicillin, chloramphenicol, gentamicin, tetracycline, and ciprofloxacin, and demonstrates intermediary resistance to daptomycin, linezolid, and vancomycin. The use of strain CBD-635 in our drug discovery studies has facilitated the identification of promising new compounds to treat infections with multiply resistant bacteria ([@B1]--[@B5]). To gain insight into the mechanism of action of potential new antimicrobial agents, we have generated CBD-635 mutants that exhibit resistance to the new compounds ([@B5]). Whole-genome sequencing will be employed to identify the mutation(s) that gives rise to resistance and therefore help elucidate the mechanism of action. To generate a reference genome for these studies, we have sequenced the genome of strain CBD-635 using Illumina next-generation DNA sequencing.

CBD-635 was grown in tryptic soy broth (TSB) overnight and genomic DNA extracted using standard methods (cells were lysed by bead beating and the genomic DNA was extracted using phenol/chloroform). Genome sequencing was performed using an Illumina HiScan SQ, which generated 8 million paired-end reads of 100 bp with an insert size of 300 bp. Of the reads generated, 25% (2 million) were randomly selected and used in a *de novo* genome assembly using the CLC Genomics Workbench software package (CLC, Denmark). This assembly generated 86 contigs with a size of \>200 bp. The 86 contigs were deposited in GenBank and annotated using the NCBI Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP) (<http://www.ncbi.nlm.nih.gov/genome/annotation_prok/>). The cumulative size of the genome is approximately 2.82 Mb, encoding 2,686 open reading frames (ORFs), comparable with similar *S. aureus* strains. Using the annotated sequence data, we performed *spa* typing and multilocus sequence typing (MLST) analysis for CBD-635. Similar to other sequenced USA100 isolates, CBD-635 is *spa* type t003 and MLST type ST5.

Nucleotide sequence accession number. {#h1}
-------------------------------------

The sequence data for this genome have been deposited in GenBank under the accession number [ASHS00000000](ASHS00000000).
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